Inositol depletion: A good or bad outcome of valproate treatment?

Future Neurology

Volumn 3, Issue 3, 2008, Pages 275-286

  Azab, Abed N ^a   Agam, Galila ^a   Kaplanski, Jacob ^a   Delbar, Vered ^a   Greenberg, Miriam L ^b  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bipolar disorder; Inositol; Inositol depletion; Lithium; Neural tube defects; Teratogenicity; Valproate

Indexed keywords

AMPHETAMINE; APOMORPHINE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; FLUVOXAMINE; FOLIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; HALOPERIDOL; INOSITOL; INOSITOL 1,4,5 TRISPHOSPHATE; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; PHOSPHATIDYLINOSITOL 3 PHOSPHATE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PILOCARPINE; PLACEBO; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; RESERPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRANSCRIPTION FACTOR E2F1; TRICHOSTATIN A; VALPROIC ACID;

ADD ON THERAPY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DIET SUPPLEMENTATION; DRUG TOLERABILITY; HUMAN; MENTAL DISEASE; MIGRAINE; NEURAL TUBE DEFECT; NEUROLOGIC DISEASE; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SCHIZOPHRENIA; SEIZURE; TERATOGENICITY; TREATMENT OUTCOME;

EID: 44149096022     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.3.275     Document Type: Review

References (135)

1. Narrow WE, Rae DS, Robins LN: Revised prevalence estimates of mental disorders in the United States: using clinical significance criterion to reconcile 2 surveys' estimates. Arch. Gen. Psychiatry 59, 115-123 (2002).
2. The Global Burden of Disease. Murray CJL, Lopez AD (Eds). Harvard University Press, MA, USA (1996).
3. Brodensen A, Licht RW, Vestergaard P, Olensen AV, Mortensen PB: Sixteen-year mortality in patients with affective disorder commenced on lithium. Br. J. Psychiatry 176, 429-433 (2000).
4. Bostwick JM, Pankratz VS: Affective disorders and suicide risk: a reexamination. Am. J. Psychiatry 157, 1925-1932 (2000).
5. Belmaker RH: Bipolar disorder. N. Engl. J. Med. 351, 476-486 (2004).
6. Gitlin M: Treatment-resistant bipolar disorder. Mol. Psychiatry 11, 227-240 (2006).
7. Bowden CL: Making optimal use of combination pharmacotherapy in bipolar disorder. J. Clin. Psychiatry 65, 21-24 (2004).
8. Judd JL, Akiskal HS, Schettler PJ et al.: The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59, 530-537 (2002).
9. Judd JL, Akiskal HS, Schettler PJ et al.: A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch. Gen. Psychiatry 60, 261-269 (2003).
10. Berridge MJ, Downes CP, Hardey MR: Lithium amplifies agonist-dependent phophatidyl-inositol responses in brain and salivary glands. Biochem. J. 206, 587-595 (1982).
11. Berridge MJ, Irvine RF: Inositol phosphates and cell signaling. Nature 341, 197-204 (1989).
12. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc. Natl Acad. Sci. USA 93, 8455-8459 (1996).
13. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS: Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741 (2001).
14. De Sarno P, Li X, Jope RS: Regulation of Akt and glycogen synthase kinase-3 β phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164 (2002).
15. Werstuck GH, Kim AJ, Brenstrum T, Ohnmacht SA, Panna E, Capretta A. Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorg. Med. Chem. Lett. 14, 5465-5467 (2004).
16. Chen G, Manji HK, Hawyer DB, Wright CB, Potter WZ: Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J. Neurochem. 63, 2361-2364 (1994).
17. Manji HK, Moore GJ, Chen G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry 46, 929-940 (1999).
18. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G: The mood stabilizer valproic acid activates mitogen-activated protein kinase and promotes neurite growth. J. Biol. Chem. 276, 31674-31683 (2001).
19. Gould TD, Quiroz JA, Signgh J, Zarate CA Jr, Manji HK: Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiatry 9, 734-755 (2004).
20. Majumder AL, Johnson MD, Henry SA: 1L-myo-inositol-1-phosphate synthase. Biochem. Biophys. Acta 1348, 245-256 (1997).
21. Bachhawat N, Mande SC: Identification of the INO1 gene of Mycobacterium tuberculosis H37Rv reveals a novel class of inositol-1-phosphate synthase enzyme. J. Mol. Biol. 291, 531-536 (1999).
22. Majumder AL, Chatterjee A, Ghosh Dastidar K, Majee M: Diversification and evolution of L-myo-inositol 1-phosphate synthase. FEBS Lett. 553, 3-10 (2003).
23. Greenberg ML, Lopes JM: Genetic regulation of phospholipid biosynthesis in yeast. Microbiol. Rev. 60, 1-20 (1996).
24. Carman GM, Henry SA. Phospholipid biosynthesis in the yeast Saccharomyces cerevisiae and interrelationship with other metabolic processes. Prog. Lipid Res. 38, 361-399 (1999).
25. Hirsch JP, Henry SA: Expression of the Saccharomyces cerevisiae inositol-1-phosphate synthase (INO1) gene is regulated by factors that affect phospholipid synthesis. Mol. Cell. Biol. 6, 3320-3328 (1986).
26. Guan G, Dai P, Shechter I: cDNA cloning and gene expression analysis of human myo-inositol 1-phosphate synthase. Arch. Biochem. Biophys. 417, 251-259 (2003).
27. Novak JE, Turner RS, Agranoff BW, Fisher SK: Differential human NT2-N neurons process a high intracellular content of the myo-inositol. J. Neurochem. 72, 1431-1440 (1999).
28. Di Daniel E, Cheng L, Maycox PR, Mudge AW. The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporter. Mol. Cell Neurosci. 32, 27-36 (2006).
29. Chauvin TR, Griswold D: Characterization of the expression and regulation of genes necessary for myo-inositol biosynthesis and transport in the seminiferous epithelium. Biol. Reproduc. 70, 744-751 (2004).
30. Seelan RS, Parthasarathy LK, Parthasarathy RN: E2F1 regulation of the human myo-inositol 1-phosphate synthase (ISYNA1) gene promoter. Arch. Biochem. Biophys. 431, 95-106 (2004).
31. Shamir A, Shaltiel G, Greenberg ML, Belmaker RH, Agans G: The effect of lithium on expression of genes for inositol biosynthetic enzymes in mouse; a comparison with the yeast model. Brain Res. Mol. Brain Res. 115, 104-110 (2003).
32. Vaden DL, Ding D, Peterson B, Greenberg ML: Lithium and valproate decrease inositol mass and increase expression of the yeast INO1 and INO2 genes for inositol biosynthesis. J. Biol. Chem. 276, 15466-15471 (2001).
33. 2+ from nonmitochondrial store in pancreatic acinar cells by inositol-1,4,5-triphosphate. Nature 306, 67-69 (1983).
34. Irvine RF, Schell MJ: Back in the water: the return of the inositol phosphates. Nat. Rev. 2, 327-338 (2001).
35. Berridge MJ: Inositol triphosphate and diacylglycerol: two interacting second messengers. Ann Rev. Biochem. 56, 159-193 (1987).
36. Hallcher LM, Sherman WR: The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem. 255, 10896-10901 (1980).
37. Atack JR, Broughton HB, Pollack SJ: Structure and mechanism of inositol monophosphatase. FEBS Lett. 361, 1-7 (1995).
38. Naccarato WF, Ray RE, Wells WW: Biosynthesis of myo-inositol in rat mammary gland. Isolation and properties of the enzymes. Arch. Biochem. Biophys. 164, 194-201 (1974).
39. Kendall DA, Nahorski SR: Acute and chronic lithium treatments influence agonist and depolarization-stimulated inositol phospholipid hydrolysis in rat cerebral cortex. J. Pharmacol. Exp. Ther. 241, 1023-1027 (1987).
40. Casebolt TL, Jope RS: Long-term lithium treatment selectively reduces receptor-coupled inositol phospholipid hydrolysis in rat brain. Biol. Psychiatry 25, 329-340 (1989).
41. Godfrey PP, McClue SJ, White AM, Wood AJ, Grahame-Smith DG: Subacute and chronic in vivo lithium treatment inhibits agonist- and sodium fluoride-stimulated inositol phosphate production in rat cortex. J. Neurochem. 52, 498-506 (1989).
42. Moore CM, Breeze JL, Kukes TF et al.: Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biol. Psychiatry 45, 1197-1202 (1999).
43. O'Donnel T, Rotzinger S, Nakashima TT, Hanstock CC, Ulrich M, Silverstone PH: Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphatases in rat brain. Brain Res. 880, 84-91 (2000).
44. Davanzo P, Thomas MA, Yue K et al.: Decreased anterior cingulate myoinositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder. Neuropsychopharmacology 24, 359-369 (2001).
45. Jope RS, Williams MB: Lithium and brain signal transduction systems. Biochem. Pharmacol. 47, 429-441 (1994).
46. Manji HK, Lenox RH: Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 16, 11-28 (1994).
47. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Handstock CC: Chronic treatment with both lithium and sodium valproate may normalize phosphoinosital cycle activity in bipolar patients. Human Psychopharmacol. 17, 321-327 (2002).
48. Shaldubina A, Stahl Z, Furszpan M et al.: Inositol deficiency diet and lithium effects. Bipolar Disord. 8, 152-159 (2006).
49. Williams RSB, Cheng L, Mudge AW, Harwood AJ: A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295 (2002).
50. Ju S, Shaltiel G, Shamir A, Again G, Greenberg ML: Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J. Biol. Chem. 279, 21759-21765 (2004).
51. Shaltiel G, Shamir A, Shapiro J et al.: Valproate decreases inositol biosynthesis. Mol. Psychiatry 56, 868-874 (2004).
52. Jope RS: Anti-bipolar therapy: mechanism of action of lithium. Mol. Psychiatry 4, 117-128 (1999).
53. Ikonomov CC, Manji HK: Molecular mechanisms underlying mood stabilization in manic-depressive illness: the phenotype challenge. Am. J. Psychiatry 156, 1506-1514 (1999).
54. Agranoff BW, Fisher SK: Inositol, lithium and the brain. Psychopharmacol. Bull. 35, 5-23 (2001).
55. Pollack SJ, Atack JR, Knowles MR et al.: Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl Acad. Sci. USA 91, 5766-5770 (1994).
56. Moore GJ, Bebchunk JM, Parish JK et al.: Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am. J. Psychiatry 156, 1902-1908 (1999).
57. Atack JR: Lithium, phosphatidylinositol signaling, and bipolar disorder. In: Bipolar Medications: Mechanism of Action. Manji HK, Bowden CL, Belmaker RH (Eds). American Psychiatric Press, Inc., Washington DC, USA (2000).
58. Moore CM, Breeze JL, Gruber SA et al.: Choline, myo-inositol and mood in bipolar disorder: a proton magnetic resonance spectroscopic imaging study of the anterior cingulated cortex. Bipolar Disord. 2, 207-216 (2000).
59. Richards MH, Belmaker RH: Epi-inositol is biochemically active in reversing lithium effect on CMP-PA. J. Neural Transmis. 103, 1281-1285 (1996).
60. Benjamins JA, Agranoff BW. Distribution and properties of CDP-diglyceride:inositol transferase from brain. J. Neurochem. 4, 513-527 (1969).
61. Shaldubina A, Ju S, Vaden D, Belmaker RH, Greenberg ML: Epi-inositol regulates expression of the yeast INO1 gene encoding inositol-1-P synthase. Mol. Psychiatry 7, 174-180 (2001).
62. Shaldubina A, Johanson RA, O'Brien WT et al.: SMIT1 haploinsufficiency causes brain inositol deficiency without affecting lithium-sensitive behavior. Mol. Genet. Metab. 88, 384-388 (2006).
63. Shaldubina A, Buccafusca R, Johanson RA et al.: Behavioral phenotyping of sodium-myo-inositol cotransporter heterozygous knockout mice with reduced brain inositol. Genes Brain Behav. 6, 253-259 (2007).
64. Einat H, Tian F, Belmaker RH, Frost JW: Myo-inositol-1-phosphate (MIP) synthase inhibition: in vivo study in rats. J Neural Transm. 115, 55-58 (2008).
65. Cherig L, Lumb M, Polgar L, Mudge W: How can the mood stabilizer VPA limit both mania and depression? Mol. Cell. Neurosci. 29, 155-161 (2005).
66. Henry SA, Donahue TF, Culbertson MR: Selection of spontaneous mutants by inositol starvation in yeast. Mol. Genom. Genet. 143, 5-11 (1975).
67. Jackson M, Shin S: Analysis of inositol starvation in an inositol requiring mutant CHO-K1. J. Cell Biol. 87, 293a (1980).
68. Minskoff SA, Gaynor PM, Greenberg ML: Mutant enrichment of Schizosaccharomyces pombe by inositol-less death. J. Bacteriol. 174, 4078-4085 (1992).
69. van Calker D, Belmaker RH: The high affinity inositol transport system - implications for the pathophysiology and treatment of bipolar disorder. Bipolar Disord. 2, 102-107 (2000).
70. +/myo-inositol cotransporter. J. Biol. Chem. 277, 35219-35224 (2002).
71. +-myo-inositol symporter expressed predominantly in the brain. EMBO J. 20, 4467-4477 (2001).
72. Nikam J, Tsukagoshi Y, Yamashita S: Isolation and characterization of two distinct myo-inositol transporter genes of Saccharomyces cerevisiae. J. Biol. Chem. 266, 11184-11191 (1991).
73. Hertz L, Wolfson M, Hertz E, Agam G, Richards M, Belmaker RH: Lithium-inositol interactions: synthesis, uptake, turnover. In: Depression: Neurobiological. Pychopathological and Therapeutic Advances. Honig A, Annseau M, van Praag HM (Eds). John Wiley and Sons Ltd, UK 519-534 (1997).
74. Aukema HM, Holub BJ: Inositol. In: Modern Nutrition in Health and Disease, 8th Edition. Shils E, Olson JA, Shike M (Ed,). Lea add, Febiger, PA, USA,466-473 (1994).
75. Ju S, Greenberg ML: 1D-myo-inositol 3-phosphate synthase: conservation, regulation, and putative target for mood stabilizers. Clin. Neurosci. Res. 4, 181-187 (2004).
76. Spector R: Myo-inositol transport through the blood-brain barrier. Neurochem. Res. 8, 785-787 (1988).
77. del No E, Shinomura T, van der Kaay J, Nicholls DG, Downes CP: Disruption by lithium of phosphoinosinde signaling in cerebellar granule cells in primary culture. J. Neurochem. 70, 1662-1669 (1998).
78. Irvine J, Umansky R, Ezrielev G, Betmaker RH: Lack of effect of inositol treatment in chronic schizophrenia. Biol. Psychiatry 33, 673-675 (1993).
79. Patishi Y, Belmaker RH, Bersudsky Y, Kofman O: A comparison of the ability of myo-inositol and epi-inositol to attenuate lithium-pilocarpine seizures in rats. Biol. Psychiatry 39, 829-832 (1996).
80. Kofman O, Agam G, Shapiro J, Spencer A. Chronic dietary mositol levels enhances locomotor activity and brain mositol levels in rats. Psychopharmacology 139, 239-242 (1998).
81. Barkai AI, Dunner DL, Gross HA, Mayo P, Fieve RR: Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder. Biol. Psychiatry 13, 65-72 (1978).
82. Levine J, Kurtzman L, Rapoport A et al.: CSF inositol does not predict antidepressant response to inositol. Short communication. J. Neurol Transmis. 103, 1457-1462 (1996).
83. Shimon H, Agam G, Belmaker RH Hyde TM, Kleiman JE: Reduced, frontal cortex levels in postmortem brain of suicide victims and patients with bipolar disorders. Am. J. Psychiatry 154, 1148-1150 (1997).
84. Einat H, Karbovski H, Korik J, Tsalah D, Belmaker RH: Inositol reduces depressive-like behaviors in two different animal models of depression. Psychopharmacology 144, 158-162 (1999).
85. Einat H, Belmaker RH: The effects of inositol treatment in animal models of psychiatric disorders. J. Affect. Disord. 62, 113-121 (2001).
86. Levine J, Barak Y, Gonsalves M et al.: Double blind study of inositol versus placebo in depression. Am. J. Psychiatry 152, 792-794 (1995).
87. Chengappa KN, Levine J, Gershon S et al.: Inositol as an add-on treatment for bipolar depression. Bipolar Disord. 2, 47-55 (2000).
88. Nierenberg AA, Ostacher MJ, Calabrese JR et al.: Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am. J. Psychiatry 163, 210-216 (2006).
89. Evins AE, Demopulos C, Culhane M et al.: Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord. 8, 168-174 (2006).
90. Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH: Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am. J. Pychiatry 152, 1084-1086 (1995).
91. Palatnik A, Frolov K, Fux M, Benjamin J: Double-blind, controlled, crossover trial of inositol versus fluvoxa mine for the treatment, of panic disorder. J. Can. Psychopharmacol. 21, 335-339 (2001).
92. Fux M, Levine J, Aviv A, Belmaker RH: Inositol treatment of obsessive-compulsive disorder. Am. J. Psychiatry 153, 1219-1221 (1996).
93. Bradley PB, Engel G, Feniuk W et al.: Proposals for the classification and nomenclature of functional receptors far 5-hydroxytryptamine. Neuropharmacology 25, 563-576 (1986).
94. Benjamin J, Dux M, Belmaker RH: Time course of inositol treatment of panic disorder. Eur. Neuropsychopharmacol. 6(Suppl. 4), 48-49 (1996).
95. Levine J, Goldberger I, Rapaport A et al.: CSF inositol levels in schizophrenia are unchanged and inositol is not therapeutic in anergic schizophrenia. Eur. Neuropsychopharmacol. 4, 487-490 (1994).
96. Barak Y, Levine J, Glasman A, Elizur A, Belmaker RH: Inositol treatment of Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 20, 729-735 (1996).
97. Drevets WC: Neuroimaging studies of mood disorders. Biol. Psychiatry 48, 813-829 (2000).
98. Strakowski SM, Delbello MP, Adler CM: The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol. Pychiatry 10, 105-116 (2005).
99. Bachmann RF, Schloesser RJ, Gould TD, Manji HK: Mood stabilizers target cellular plasticity and resilience cascades: implications for the development of novel therapeutics. Mol. Neurobiol. 32, 173-202 (2005).
100. Einat H, Manji HK: Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorders. Biol. Psychiatry 59, 1160-1171 (2006).
101. Loescher W: Valproic acid mechanisms of action. In: Antiepileptic Drugs. Levy RH, Mattson RH, Meldrum BS, Perucca E (Eds). Lippincott Williams & Wilkins, PA, USA 767-779 (2002).
102. Perucca E: Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16, 695-714 (2002).
103. Bowden CL, Brugger AM, Swann AC et al.: Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA 271, 918-924 (1994). Erraturn JAMA 271, 1830 (1994).
104. Bowden CL, Calabrese JR, McElroy SL et al.: A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry 57, 481-489 (2000).
105. Ghose K, Niven B: Prophylactic sodium valproate therapy in patients with drug-resistant migraine. Methods Find. Exp. Clin. Pharmacol. 20, 353-359 (1998).
106. Mitsikostas DD, Polychronidis I: Valproate versus flunarizine in migraine prophylaxis: a randomized, double-open, clinical trial. Funct. Neurol. 12, 267-276 (1997).
107. Verotti A, Tana M, Pelliccia P, Chiarelli F, Latini G: Recent advances on neual tube defects with special reference to valproic acid, Endocr. Metab. Immune Disord. Drug Targets 6, 25-31 (2006).
108. Robert E, Rosa F: Valproate and birth defects. Lancet 2, 1142 (1983).
109. Robert E, Gulband P: Maternal valproic acid and congenital neural tube defects. Lancet 2, 937 (1982).
110. Nan H, Hauck RS, Ehlers K: Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69, 310-321 (1991).
111. Omtzigt JG, Los FJ, Grobbee DE et al.: The risk of spina bifida aperta after first-trimester exposure to valproate in prenatal cohort. Neurology 42, 119-125 (1992).
112. Duncan S, Mercho S, Lopes-Cendes I et al.: Repeated neural tube defects and valproate monotherapy suggest a pharmacological abnormality. Epilepsia 42, 750-753 (2001).
113. Rosenberg G: The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell. Mol. Life Sci. 64, 2090-2103 (2007).
114. Johannessen CU: Mechanisms of action of valproare: a commentatory. Neurochem. Int. 37, 103-110 (2007).
115. Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB: Association of valproate-induced teratogenesis with historic deacetylase inhibition in vivo. FASEB J. 19, 1166-1168 (2005).
116. Vulcano F, Ciccarelli C, Mattia G et al.: HDAC inhibition is associated to valproic acid induction of early megakaryocytic markers. Exp. Cell Res. 312, 1590-1597 (2006).
117. Palaty J, Abbott S: Structure-activity realtionship of unsaturated analogues of valproic acid. J. Med. Chem. 38, 3398-3406 (1995).
118. Zhao Q, Behringer RR, de-Crombrugghe B: Prenatal folic acid treatment suppresses acrania and meroanencephaly in mice mutant for the Cart1 homebox gene. Nat. Gen. 13, 275-283 (1996).
119. Shin JH, Shiota K: Folic acid supplementation of pregnant mice. suppresses heat-induced neural tube defects in the offspring. J. Nutr. 129, 2070-2073 (1999).
120. MRC Vitamin Study Research Group: Prevention of neural tube defects: results of the medical research council vitamin study. MRC Vitamin Study Research Group. Lancet 338, 131-137 (1991).
121. Czeizel AE, Dudas I: Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N. Engl. J. Med. 327, 1832-1835 (1992).
122. Honcin MA, Paulozzi LJ, Mathews TJ, Erikson JD, Wong LY: Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects. JAMA 285, 2981-2986 (2001).
123. Eichholzer M, Tonz O, Zimmermann R: Folic acid: a public health problem. Lancet 367, 1352-1361 (2006).
124. Grosse SD, Collins JS: Folic acid supplementation and neural tube defect occurrence prevention. Birth Defects Res. A Clin. Mol. Teratol. 79, 737-742 (2007).
125. De Wals P, Tairou F, Van Allen MI et al.: Reduction in neural-tube defects after folic acid fortification in Canada. N. Engl. J. Med. 357, 135-142 (2007).
126. Greene ND, Copp AJ: Inositol prevents folate-resistant neural tube defects in the mouse. Nat. Med. 3, 60-66 (1997).
127. Reece EA, Khandewal M, Wu YK, Borenstein M: Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats. Am J. Obstet Gynecol. 176, 536-539 (1997).
128. Haneda M, Kikkawa R, Arimura T et al.: Glucose inhibits myo-inositol uptake and reduces myo-inositol content in cultured rat glomerular mesangial cells. Metabolism 39, 40-45 (1990).
129. Beemster P, Groenen P, Steegers-Theunissen R: Involvement of inositol in reproduction. Nutr. Rev. 60, 80-87 (2002).
130. Cogram P, Hynes A, Dunlevy LP, Greene ND, Copp AJ: Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. Hum. Mol. Genet. 13, 7-14 (2004).
131. Ting SB, Wailanowski T, Auden A et al.: Inositol- and folate-resistant neural tube defects in mice lacking the epithelial-specific factor GrhI-3. Nat. Med. 9, 1513-1519 (2005).
132. Cogram, P, Tesh S, Tesh J et al.: D-chiro- inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum. Reprod 17, 2451-2458 (2002).
133. Cavalli P, Copp AJ: Inositol and folate resistant neural tube defects. J. Med Genet. 39, E5 (2002).
134. Shaw GM, Carmichael SL, Yang W, Schaffer DM: Periconceptional dietary intake of myo-inositol and neural tube defects in offspring. Birth Defects Res. A Clin. Mol. Teratol. 73, 184-187 (2005).
135. Massa V, Wlodarczyk B, Giavini E, Finnell RH: Myo-inositol enhances tertogenicity of valproic acid in the mouse. Birth Defects Res. 76, 200-204 (2006).